Jaqueline Willemann Rogerio

Statistics

Publications

Citations

226

H-Index

Active since

2003

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Pennsylvania

Novartis (United States)

USC Norris Comprehensive Cancer Center

Novartis (Switzerland)

Jaqueline Willemann Rogerio is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and pharmacotherapy.

Publications per year

2003–2023

Publications

Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis

Peter P. Sun, Michael Kohrman, Jamae Liu et al. · Current Medical Research and Opinion · 2012 · 62 citations

Medicine, Neurological Surgery, Surgery +9

Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma

Michael K. Wong, Ateesha F. Mohamed, Brett Hauber et al. · Journal of Medical Economics · 2012 · 41 citations

Pharmacy, Oncology, Pharmacotherapy +12

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · Journal of Clinical Oncology · 2021 · 38 citations

Medicine, Oncology, Perioperative Medicine +15

Surgical resection of subependymal giant cell astrocytomas (SEGAs) and changes in SEGA-related conditions: a US national claims database study

Peter P. Sun, Darcy A. Krueger, Jamae Liu et al. · Current Medical Research and Opinion · 2012 · 19 citations

Medicine, Neurosurgery, Surgery +9

Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study.

Patrick B. Johnston, Lauren Pinter‐Brown, Jaqueline Willemann Rogerio et al. · Blood · 2012 · 19 citations

Medicine, Oncology, Pharmacotherapy +10

1–5 of 9